Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207321 | 1.00 | ACP1 (0.51) | ACP1HTR7MAOBAKR1C3TAAR1 | |
| SCHEMBL29922075 | 0.87 | MAOB (0.54) | ACP1MAOBAKR1C3TAAR1HSD17B2 | |
| SCHEMBL23630643 | 0.87 | MAOB (0.54) | ACP1MAOBAKR1C3TAAR1HSD17B2 | |
| SCHEMBL21586160 | 0.82 | ACP1 (0.47) | ACP1HTR7MAOBAKR1C3TAAR1 | |
| SCHEMBL31207325 | 0.82 | ACP1 (0.47) | ACP1HTR7MAOBAKR1C3TAAR1 | |
| SCHEMBL21586173 | 0.80 | HRAS (0.58) | ACP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31207327 | 0.80 | ACP1 (0.45) | ACP1HTR7AKR1C3TUBB4ATUBB | |
| SCHEMBL21586170 | 0.80 | ACP1 (0.45) | ACP1HTR7AKR1C3TUBB4ATUBB | |
| SCHEMBL31207319 | 0.80 | HRAS (0.58) | ACP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21586177 | 0.75 | ACP1 (0.47) | ACP1DHODHTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | claimed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | claimed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | claimed |
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | ACP1 729/4885HTR7 4669/4885MAOB 4147/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | ACP1 729/4885HTR7 4669/4885MAOB 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.